New lung cancer pill enters first human trials
NCT ID NCT06955988
Summary
This is the first study in people testing a new oral medication called AST2303 for advanced non-small cell lung cancer. The main goals are to find a safe dose, understand how the body processes the drug, and look for early signs that it might help shrink tumors. The study will enroll about 120 adults whose cancer has spread and who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.